SEC Filing Summary: Enochian Biosciences Inc. (ENOB)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. on May 26, 2022, covering the date of the earliest event reported on May 25, 2022. The registrant is a Delaware corporation with principal executive offices in North Hollywood, California. The filing serves to disclose a press release issued on May 25, 2022, which is attached as Exhibit 99.1.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As this is a Current Report under Item 8.01 (Other Events) referencing a press release, it does not contain audited financial statements or detailed financial data within the body of the document.
Material Changes
The document does not detail specific material changes to financial performance or operations within the text provided. The sole material event disclosed is the issuance of a press release on May 25, 2022. The content of that press release is not included in the filing text, only referenced as an exhibit.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors within the provided text. The document explicitly states that the information in Item 8.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the press release dated May 25, 2022, by reviewing Exhibit 99.1, as the specific details of the announcement are not in the main text.
- Confirm the company's current trading status on The Nasdaq Stock Market LLC under the symbol ENOB.
- Note that the filing is signed by Mark R. Dybul, Chief Executive Officer, on May 26, 2022.
- Be aware that the press release information is furnished and not legally filed under Section 18 of the Exchange Act.